Uterine sarcoma and aromatase inhibitors: Tom Baker cancer centre experience and review of the literature

International Journal of Gynecological Cancer

Volumn 22, Issue 6, 2012, Pages 1006-1012

  Altman, Alon D ^a   Nelson, Gregg S ^b   Chu, Pamela ^b   Nation, Jill ^b   Ghatage, Prafull ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Adjuvant treatment; Aromatase inhibitors; Gynecologic Surgery; Uterine sarcoma

Indexed keywords

ANASTROZOLE; EXEMESTANE; LETROZOLE; MEGESTROL ACETATE; PROGESTERONE RECEPTOR;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; CANADA; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CASE REPORT; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; EDEMA; ENDOMETRIUM SARCOMA; FEMALE; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; MOOD DISORDER; OMENTECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SALPINGOOOPHORECTOMY; SIDE EFFECT; SWELLING; TREATMENT RESPONSE; UTERUS SARCOMA; WEIGHT GAIN;

ADULT; AROMATASE INHIBITORS; FEMALE; HUMANS; HYSTERECTOMY; LEIOMYOSARCOMA; MIDDLE AGED; NITRILES; RETROSPECTIVE STUDIES; SARCOMA, ENDOMETRIAL STROMAL; TRIAZOLES; UTERINE NEOPLASMS;

EID: 84863623805     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31825b7de8     Document Type: Review

References (49)

1. Somoye G, Lawton H, Havenga S. Endometrial stromal sarcoma: experience from a district hospital and literature review. Eur J Gynaecol Oncol. 2009;30:664-667.
2. Ioffe YJ, Li AJ, Walsh CS, et al. Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles. Gynecol Oncol. 2009;115:466-471.
3. Nordal RR, Thoresen SO. Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality. Eur J Cancer. 1997;33:907-911.
4. Marchese MJ, Liskow AS, Crum CP, et al. Uterine sarcomas: a clinicopathologic study, 1965-1981. Gynecol Oncol. 1984;18:299-312.
5. Kurman R, ed. Blaustein's Pathology of the Female Genital Tract. 5th ed. New York, NY: Springer-Verlag New York; 2002.
6. Berek JS, Hacker NF, ed. Practical Gynecologic Oncology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
7. Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993;71:1702-1709.
8. Dahhan T, Fons G, Buist MR, et al. The efficacy of hormonal treatment for residual or recurrent low-grade endometrial stromal sarcoma. A retrospective study. Eur J Obstet Gynecol Reprod Biol. 2009;144:80-84.
9. Reich O, Regauer S. Hormonal therapy of endometrial stromal sarcoma. Curr Opin Oncol. 2007;19:347-352.
10. George M, Pejovic MH, Kramar A. Uterine sarcomas: prognostic factors and treatment modalitiesVstudy on 209 patients. Gynecol Oncol. 1986;24:58-67.
11. Amant F, De Knijf A, Van Calster B, et al. Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma. Br J Cancer. 2007;97:1194-1199.
12. Kitchener HC, Trimble EL, Endometrial Cancer Working Group of the Gynecologic Cancer Intergroup. Endometrial cancer state of the science meeting. Int J Gynecol Cancer. 2009;19:134-140.
13. Gadducci A, Cosio S, Romanini A, et al. The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol. 2008;65:129-142.
14. Reed NS, Mangioni C, Malmstrom H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (Protocol 55874). Eur J Cancer. 2008;44:808-818.
15. Gould RE, Garcia AA. Update on aromatase inhibitors in breast cancer. Curr Opin Obstet Gynecol. 2006;18:41-46.
16. Barker LC, Brand IR, Crawford SM. Sustained effect of the aromatase inhibitors Anastrozole and Letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. Curr Med Res Opin. 2009;25:1105-1109.
17. Maluf FC, Sabbatini P, Schwartz L, et al. Endometrial stromal sarcoma: objective response to Letrozole. Gynecol Oncol. 2001;82:384-388.
18. Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol. 1996;14:2000-2011.
19. Reich O, Regauer S. Survey of adjuvant hormone therapy in patients after endometrial stromal sarcoma. Eur J Gynaecol Oncol. 2006;27:150-152.
20. Tzakas E, Liu S, Todd RW, et al. Hormonal therapy with Letrozole prior to surgical management of recurrent metastatic low-grade endometrial stromal sarcoma (LGESS). J Obstet Gynaecol. 2009;29:778-779.
21. Chu MC, Mor G, Lim C, et al. Low-grade endometrial stromal sarcoma: hormonal aspects. Gynecol Oncol. 2003;90:170-176.
22. Landreat V, Paillocher N, Catala L, et al. Low-grade endometrial stromal sarcoma of the uterus: review of 10 cases. Anticancer Res. 2008;28:2869-2874.
23. Amant F, Vergote I, Moerman P. The classification of a uterine sarcoma as 'high-grade endometrial stromal sarcoma' should be abandoned. Gynecol Oncol. 2004;95:412-413; author reply 413.
24. Pink D, Lindner T, Mrozek A, et al. Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol. 2006;101:464-469.
25. Shoji K, Oda K, Nakagawa S, et al. Aromatase inhibitor Anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report. Med Oncol. 2010.
26. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
27. Leunen M, Breugelmans M, De Sutter P, et al. Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole. Gynecol Oncol. 2004;95:769-771.
28. Leiser AL, Hamid AM, Blanchard R. Recurrence of prolactin-producing endometrial stromal sarcoma with sex-cord stromal component treated with progestin and aromatase inhibitor. Gynecol Oncol. 2004;94:567-571.
29. Krauss K, Bachmann C, Hartmann JT, et al. Management of late recurrence of a low-grade endometrial stromal sarcoma (LGESS): treatment with letrozole. Anticancer Res. 2007;27:3477-3480.
30. Brechot JM, Kamboucher M, Brauner M, et al. Pulmonary metastases from endometrial stromal sarcoma may benefit from hormone therapy. Rev Mal Respir. 2007;24:69-72.
31. Alkasi O, Meinhold-Heerlein I, Zaki R, et al. Long-term disease-free survival after hormonal therapy of a patient with recurrent low grade endometrial stromal sarcoma: a case report. Arch Gynecol Obstet. 2009;279:57-60.
32. Spano JP, Soria JC, Kambouchner M, et al. Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcoma. Med Oncol. 2003;20:87-93.
33. O'Cearbhaill R, Zhou Q, Iasonos A, et al. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecol Oncol. 2010;116:424-429.
34. Hardman MP, Roman JJ, Burnett AF, et al. Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor. Obstet Gynecol. 2007;110:518-520.
35. Gottwald L, Gora E, Korczynski J, et al. Primary uterine rhabdomyosarcoma in a patient with a history of breast cancer and gastrointestinal stromal tumor. J Obstet Gynaecol Res. 2008;34:721-725.
36. Garuti G, Cellani F, Centinaio G, et al. Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors. Gynecol Oncol. 2006;103:599-603.
37. Reich O, Regauer S. Aromatase expression in low-grade endometrial stromal sarcomas: an immunohistochemical study. Mod Pathol. 2004;17:104-108.
38. Garrett A, Quinn MA. Hormonal therapies and gynaecological cancers. Best Pract Res Clin Obstet Gynaecol. 2008;22:407-421.
39. Bonte J. Recent data about endometrial carcinoma: potential of anti-aromatase agents. Eur J Gynaecol Oncol. 2001;22:96-98.
40. Bellone S, Shah HR, McKenney JK, et al. Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole. Am J Obstet Gynecol. 2008;199:e7Ye10.
41. Rose PG, Brunetto VL, VanLe L, et al. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2000;78:212-216.
42. Lai CH, Huang HJ. The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer. Curr Opin Obstet Gynecol. 2006;18:29-34.
43. Oliva E, Clement PB, Young RH. Endometrial stromal tumors: an update on a group of tumors with a protean phenotype. Adv Anat Pathol. 2000;7:257-281.
44. Norris HJ, Taylor HB. Mesenchymal tumors of the uterus. I. A clinical and pathological study of 53 endometrial stromal tumors. Cancer. 1966;19:755-766.
45. Haberal A, Kayikcioglu F, Boran N, et al. Endometrial stromal sarcoma of the uterus: analysis of 25 patients. Eur J Obstet Gynecol Reprod Biol. 2003;109:209-213.
46. Burke C, Hickey K. Treatment of endometrial stromal sarcoma with a gonadotropin-releasing hormone analogue. Obstet Gynecol. 2004;104:1182-1184.
47. Toro JR, Travis LB, Wu HJ, et al. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases. Int J Cancer. 2006;119:2922-2930.
48. Hensley ML, Ishill N, Soslow R, et al. Adjuvant gemcitabine plus docetaxel for completely resected stages IYIV high grade uterine leiomyosarcoma: Results of a prospective study. Gynecol Oncol. 2009;112:563-567.
49. Omura GA, Blessing JA, Major F, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol. 1985;3:1240-1245.